Sharpe ratio
0.50Return earned for the risk taken.
Moderate
Moderate risk-adjusted returns. The reward for risk has been average.
+10.45%1Y Absolute Return
-0.65%1D
Loading NAV history…
Past performance is not an indicator of future returns.
Returns calculator comparison
Compare an illustrative investment outcome across return assumptions.
| Asset | Projected corpus | Total invested | Gain | Annual return |
|---|---|---|---|---|
| Tata India Pharma & Healthcare Fund-Direct Plan-GrowthFund 5Y annualised return | ₹10,87,167 | ₹7,32,612 | ₹3,54,555 | +15.80% |
| EPFIllustrative annual assumption | ₹8,95,132 | ₹7,32,612 | ₹1,62,520 | +8.25% |
| Residential propertyIllustrative annual assumption | ₹8,67,662 | ₹7,32,612 | ₹1,35,050 | +7.00% |
| PPFIllustrative annual assumption | ₹8,69,819 | ₹7,32,612 | ₹1,37,207 | +7.10% |
| Bank fixed depositIllustrative annual assumption | ₹8,56,981 | ₹7,32,612 | ₹1,24,369 | +6.50% |
| GoldIllustrative annual assumption | ₹8,67,662 | ₹7,32,612 | ₹1,35,050 | +7.00% |
| Savings accountIllustrative annual assumption | ₹7,86,827 | ₹7,32,612 | ₹54,215 | +3.00% |
Illustration only. Fund results use the available NAV-derived annualised return and can be negative. Reference rows are assumptions, not current quoted rates or guaranteed returns; property excludes transaction costs, taxes, and liquidity constraints. Mutual fund investments are subject to market risk.
Wealth multiple
₹1 became₹1.14
₹1 Lakh since launch₹1.14 Lakh
Fund age10.9 yrs
Fund information
Scheme code135810
ISININF277K019A3
BenchmarkBSE Healthcare TRI
CategoryEquity Scheme - Sectoral/ Thematic
Expense ratio1.06%
Exit loadExit load of 0.25% if redeemed within 30 days.
Minimum SIP₹100 SIP
Return comparison
209th / 932 in category| Period | Fund | Benchmark | Category avg |
|---|---|---|---|
| 1M | +137.03% | — | — |
| 3M | +0.33% | — | — |
| 6M | +13.75% | — | — |
| 1Y | +10.45% | — | +4.16% |
| 3Y | +19.01% | — | +12.54% |
| 5Y | +15.80% | — | +10.04% |
| 10Y | +15.70% | — | — |
| Since Launch | +13.50% | — | — |
Risk-adjusted performance
Every measure is expanded with a plain-language reading of the latest calculated value.
Sortino ratio
0.73Return earned while limiting downside risk.
Moderate
Moderate downside risk-adjusted performance.
Standard deviation
12.13%How much the fund’s returns fluctuate over time.
Moderate volatility
Returns can move up and down noticeably.
Beta
—How closely the fund moves with the market.
Unavailable
This measure needs sufficient fund and benchmark history to calculate.
Alpha
—Extra return generated above the benchmark.
Unavailable
This measure needs sufficient fund and benchmark history to calculate.
Treynor ratio
—Return earned for each unit of market risk taken.
Unavailable
This measure needs sufficient fund and benchmark history to calculate.
Calmar ratio
0.68How well the fund rewarded investors relative to its biggest decline.
Good
Good return relative to the drawdowns experienced.
Information ratio
—How consistently the fund outperformed its benchmark.
Unavailable
This measure needs sufficient fund and benchmark history to calculate.
Portfolio allocation
Latest disclosed portfolio mix
Asset allocation
Allocation data has not been disclosed.
Market cap allocation
Sector allocation
Equity exposure by sector
Top holdings
10 of 39 disclosed positions
| Holding | Sector | Instrument type | Weight |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd | Healthcare | Equity | 8.59% |
| Divi's Laboratories Ltd | Healthcare | Equity | 6.36% |
| Healthcare Global Enterprises Ltd | Healthcare | Equity | 5.85% |
| Abbott India Ltd | Healthcare | Equity | 5.63% |
| Rainbow Childrens Medicare Ltd | Healthcare | Equity | 4.9% |
| Glaxosmithkline Pharmaceuticals Ltd | Healthcare | Equity | 4.66% |
| Cipla Ltd | Healthcare | Equity | 4.53% |
| Dr. Reddy's Laboratories Ltd | Healthcare | Equity | 4.25% |
| Max Healthcare Institute Ltd | Healthcare | Equity | 4.07% |
| Apollo Hospitals Enterprise Ltd | Healthcare | Equity | 3.9% |
Fund management
RA
Rajat Srivastava
Since 2024 · Prior to joining Tata Mutual Fund, he has worked with Incred Asset Management, Kotak Investment Banking, Emkay Global, Evalueserve and Motilal Oswal Financial Services
Mr. Srivastava has done BBA (Banking & Insurance), PGDM - IMT Ghaziabad
Compare similar funds
No comparable category funds are available yet.
Summary
A high riskometer-risk equity scheme - sectoral/ thematic fund. Ahead of its category average over 3Y by 6.5 points. Healthcare makes up 92% — trouble in that sector hits the whole fund.
Strengths
- Ahead of its category average over 3Y by 6.5 points.
- Losses and swings stayed contained — worst fall -19.8%, volatility 12.1%.
- Ranks 209 of 932 in its category over 1 year.
Weaknesses
- None
Ideal investor
- Needs a 5–7+ years horizon to ride out its high riskometer risk level.
- Good fit for SIPs — spreading purchases smooths out 12.1% volatility.
Risk drivers
- Healthcare makes up 92% — trouble in that sector hits the whole fund.